[1]钞卫光,张晶,陆克义.分化型甲状腺癌腹盆部131I显像假阳性分析[J].国际放射医学核医学杂志,2017,41(5):370-373.[doi:10.3760/cma.j.issn.1673-4114.2017.05.012]
 Chao Weiguang,Zhang Jing,Lu Keyi.Analysis of differentiated thyroid cancer false-positive uptake in abdominal cavity and pelvic cavity on radioiodine whole-body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):370-373.[doi:10.3760/cma.j.issn.1673-4114.2017.05.012]
点击复制

分化型甲状腺癌腹盆部131I显像假阳性分析(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第5期
页码:
370-373
栏目:
综述
出版日期:
2017-09-25

文章信息/Info

Title:
Analysis of differentiated thyroid cancer false-positive uptake in abdominal cavity and pelvic cavity on radioiodine whole-body scan
作者:
钞卫光 张晶 陆克义
030001 太原, 山西医科大学第一医院核医学科
Author(s):
Chao Weiguang Zhang Jing Lu Keyi
Department of Nuclear Medicine, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
分化型甲状腺癌碘放射性同位素腹盆腔假阳性
Keywords:
Differentiated thyroid carcinomaIodine radioisotopesAbdominal and pelvic cavityFalse-positive
DOI:
10.3760/cma.j.issn.1673-4114.2017.05.012
摘要:
全身131I显像时,除了甲状腺组织、分化型甲状腺癌(DTC)转移及复发灶显影外,非甲状腺组织来源的假阳性病变也常不同程度地摄取131I而显影。探讨DTC患者腹盆部非甲状腺组织来源的假阳性病变摄取131I的不同原因,分析其可能存在的病变信息,可以给临床诊疗提供必要的帮助,笔者就有关腹盆部131I显像假阳性研究进行综述。
Abstract:
When it comes to 131I radioiodine whole-body scan, normal thyroid tissue and differentiated thyroid cancer(DTC) can uptake radioiodine, so does the non-thyroid tissue to some extent. The understanding of the possible explanations for the abnormal radioiodine uptake in the abdominal cavity and pelvic cavity tissue on I-131 radioiodine whole-body scan is of great importance to clinical diagnosis. The relevant reports about this field are reviewed.

参考文献/References:

[1] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4):264-278. DOI:10.3760/cma.j.issn.2095-2848.2014.04.002. Chinese society of nuclear medicine. 131I treatment of differentiated thyroid cancer guidelines (2014 update)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4):264-278.
[2] Glazer DI, Brown RK, Wong KK, et al. SPECT/CT evaluation of unusual physiologic radioiodine biodistributions:pearls and pitfalls in image interpretation[J]. Radiographics, 2013, 33(2):397-418. DOI:10.1148/rg.332125051.
[3] Oh JR, Ahn BC. False-positive uptake on radioiodine whole-body scintigraphy:physiologic and pathologic variants unrelated to thyroid cancer[J]. Am J Nucl Med Mol Imaging, 2012, 2(3):362-385.
[4] Omür O, Akgün A, Ozcan Z, et al. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans[J]. Clin Nucl Med, 2009, 34(1):11-14. DOI:10.1097/RLU.0b013e31818f433c.
[5] Jun S, Lee JJ, Park SH, et al. Prediction of treatment response to 131I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer[J]. Ann Nucl Med, 2015, 29(7):603-612. DOI:10. 1007/s12149-015-0983-5.
[6] Seok JW, Kim SJ, Kim IJ, et al. Normal gallbladder visualization during post-ablative iodine-131 scan of thyroid cancer[J]. J Korean Med Sci, 2005, 20(3):521-523. DOI:10.3346/jkms.2005.20.3.521.
[7] Brucker-Davis F, Reynolds JC, Skarulis MC, et al. False-positive iodine-131 whole-body scans due to cholecystitis and sebaceous cyst[J]. J Nucl Med, 1996, 37(10):1690-1693.
[8] Wapnir IL, van De Rijn M, Nowels K, et al. Immunohistochemical profile of the Sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections[J]. J Clin Endocrinol Metab, 2003, 88(4):1880-1888. DOI:10.1210/jc.2002-021544.
[9] Caplan RH, Gundersen GA, Abellera RM, et al. Uptake of iodine-131 by a Meckel’s diverticulum mimicking metastatic thyroid cancer[J]. Clin Nucl Med, 1987, 12(9):760-762.
[10] Zucker RJ, Bradley YC, Toney MO, et al. Gastric volvulus detected with iodine-131 whole-body imaging[J]. Clin Nucl Med, 2000, 25(4):303-305. DOI:10.1097/00003072-200004000-00020.
[11] Borkar S, Grewal R, Schoder H. I-131 uptake demonstrated in the appendix on a posttreatment scan in a patient with thyroid cancer[J]. Clin Nucl Med, 2008, 33(8):551-552. DOI:10.1097/RLU.0b013e31817deb7e.
[12] Soyluo?lu Demir S, Ege Akta G, Polat A, et al. Ectopic pelvic kidney mimicking sacral metastasis on post-therapy iodine-131 scan of a thyroid cancer patient[J]. Mol Imaging Radionucl Ther, 2017, 26(1):43-46. DOI:10.4274/mirt.75436.
[13] Husmann L, Scheffel H, Stumpe K, et al. Pyelocaliceal diverticulum as a rare pitfall in I-131 post-therapy scanning[J]. Clin Nucl Med, 2010, 35(6):443-444. DOI:10.1097/RLU.0b013e3181db4aa8.
[14] Mattern M, Staab E. I-131 localization in hematocolpos:a differential diagnosis consideration for pelvic I-131 uptake[J]. Clin Nucl Med, 2007, 32(8):659-660. DOI:10.1097/RLU.0b013e3180a1ad35.
[15] Rachinsky I, Driedger A. Iodine-131 uptake in a menstruating uterus:value of SPECT/CT in distinguishing benign and metastatic Iodine-positive lesions[J]. Thyroid, 2007, 17(9):901-902. DOI:10. 1089/thy.2007.0084.
[16] Buton L, Morel O, Gault P, et al. False-positive Iodine-131 wholebody scan findings in patients with differentiated thyroid carcinoma:report of 11 cases and review of the literature[J]. Ann Endocrinol (Paris), 2013, 74(3):221-230. DOI:10.1016/j.ando.2013.05.007.
[17] Ranade R, Pawar S, Mahajan A, et al. Unusual false positive radioiodine uptake on 131I whole body scintigraphy in three unrelated organs with different pathologies in patients of differentiated thyroid carcinoma:a case series[J]. World J Nucl Med, 2016, 15(2):137-141. DOI:10.4103/1450-1147.176884.
[18] Campennì A, Ruggeri RM, Giovinazzo S, et al. Radioiodine uptake in a renal cyst mimicking a metastasis in a patient affected by differentiated thyroid cancer:case report and review of the literature[J]. Ann Nucl Med, 2014, 28(5):472-476. DOI:10.1007/s12149-014-0816-y.
[19] Bural GG, Peel RL, Mountz JM. Benign epithelial cyst mimicking thyroid cancer metastasis:a false-positive finding on post-therapy I-131 scan[J]. Clin Nucl Med, 2012, 37(1):88-90. DOI:10.1097/RLU. 0b013e31822920a3.
[20] Jang HY, Kim BH, Kim WJ, et al. False-positive radioiodine uptake in a functional ovarian cyst in a patient treated with total thyroidectomy for papillary cancer[J]. Intern Med, 2013, 52(20):2321-2323. DOI:10.2169/internalmedicine.52.0786.
[21] Isoda T, Baba S, Maruoka Y, et al. Nabothian cyst a predominant cause of false-positive Iodine uptake in uterus:comparison of SPECT/CT and pelvic MRI[J]. Clin Nucl Med, 2014, 39(8):680-684. DOI:10.1097/RLU.0000000000000504.
[22] Wu SY, Kollin J, Coodley E, et al. I-131 total-body scan:localization of disseminated gastric adenocarcinoma. Case report and survey of the literature[J]. J Nucl Med, 1984, 25(11):1204-1209.
[23] Hirata K, Shiga T, Kubota KC, et al. Radioiodine therapy for thyroid cancer depicted uterine leiomyoma[J]. Clin Nucl Med, 2009, 34(3):180-181. DOI:10.1097/RLU.0b013e3181966ff0.
[24] Elgazzar AH, Mahmoud AR, Abdel-Dayem HM. Technetium-99m DTPA uptake in uterine leiomyoma[J]. Clin Nucl Med, 1988, 13(1):29-31.
[25] 寇莹,刘建中,郝新忠,等. 甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J]. 国际放射医学核医学杂志, 2014, 38(1):15-18, 58. DOI:10.3760/cma.j.issn.1673-4114.2014.01.004. Kou Y, Liu JZ, Hao XZ, et al. Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J]. Int J Radiat Med Nucl Med, 2014, 38(1):15-18, 58.
[26] Lakshmanan M, Reynolds JC, Del Vecchio S, et al. Pelvic radioiodine uptake in a rectal wall teratoma after thyroidectomy for papillary carcinoma[J]. J Nucl Med, 1992, 33(10):1848-1850.
[27] Ranade R, Rachh S, Basu S. Late manifestation of peritoneal strumosis and widespread functioning lesions in the setting of Struma Ovarii simulating "Highly Differentiated Follicular Carcinoma" (HDFCO)[J]. J Nucl Med Technol, 2015, 43(3):231-233. DOI:10.2967/jnmt.114.149294.
[28] Flug J, Lameka K, Lee R, et al. False-positive I-131 uptake by an ovarian serous cystadenofibroma[J]. Clin Nucl Med, 2012, 37(2):178-180. DOI:10.1097/RLU.0b013e31823933d2.
[29] Do Vale RH, Sado HN, Danilovic DL, et al. Incidental diagnosis of struma ovarii through radioiodine whole-body scanning:incremental role of SPECT/CT[J]. Radiol Bras, 2016, 49(2):126-127. DOI:10. 1590/0100-3984.2015.0027.
[30] Mebarki M, Menemani A, Medjahedi A, et al. Radioiodine accumulation in a giant ovarian cystadenofibroma detected incidentally by 131-I whole body scans[J/OL]. Case Rep Radiol, 2012, 2012(6):295617[2017-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483684/pdf/CRIM.RADIOLOGY2012-295617.pdf.DOI:10.1155/2012/295617.
[31] Candido J, Hagemann T. Cancer-related inflammation[J]. J Clin Immunol, 2013, 33(Suppl 1):S79-84. DOI:10.1007/s10875-012-9847-0.
[32] Caronni N, Savino B, Bonecchi R. Myeloid cells in cancer-related inflammation[J]. Immunobiology, 2015, 220(2):249-253. DOI:10. 1016/j.imbio.2014.10.001.
[33] Acar E, Akgun A, Kocacelebi K, et al. I-131 uptake in malignant fibrous histiocytoma[J]. Clin Nucl Med, 2007, 32(7):580-581. DOI:10.1097/RLU.0b013e3180646a44.
[34] Wang PW, Chen HY, Li CH, et al. Uptake of I-131 by an abdominal neurilemoma mimicking metastatic thyroid carcinoma[J]. Clin Nucl Med, 1993, 18(11):964-966.
[35] 黄蕤, 匡安仁. 18F-FDG正电子断层显像在分化型甲状腺癌中的应用进展[J]. 生物医学工程学杂志, 2014, 31(2):445-451. DOI:10.7507/1001-5515.20140082. Huang R, Kuang AR. Application progress of 18F-FDG positron emission tomograph in differentiated thyroid cancer[J]. J Biomed Eng, 2014, 31(2):445-451.
[36] Ruhlmann M, Jentzen W, Ruhlmann V, et al. High level of agreement between pretherapeutic 124I PET and intratherapeutic 131I imaging in detecting Iodine-Positive thyroid cancer metastases[J]. J Nucl Med, 2016, 57(9):1339-1342. DOI:10.2967/jnumed.115. 169649.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
 Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
 Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
 Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
 yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
 Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[6]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
 Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[7]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
 Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[8]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
 Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[9]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
 Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b(Pseudomonas putida)administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[10]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
 Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[11]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
 Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[12]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
 Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[13]孔维静,徐颖.综合干预措施下评估首次131I清甲治疗对分化型甲状腺癌患者唾液腺的慢性损伤[J].国际放射医学核医学杂志,2018,(1):30.[doi:10.3760/cma.j.issn.1673-4114.2018.01.006]
 Kong Weijing,Xu Ying.Assessment of the chronic injury of salivary glands in patients with differentiated thyroid cancer who underwent comprehensive intervention measures with first 131I clearing therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):30.[doi:10.3760/cma.j.issn.1673-4114.2018.01.006]
[14]南楠,朱小华.分化型甲状腺癌131I显像假阳性的原因分析[J].国际放射医学核医学杂志,2018,(1):62.[doi:10.3760/cma.j.issn.1673-4114.2018.01.012]
 Nan Nan,Zhu Xiaohua.Analysis of the false positive findings on 131I whole-body scan in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):62.[doi:10.3760/cma.j.issn.1673-4114.2018.01.012]

备注/Memo

备注/Memo:
收稿日期:2017-06-19。
通讯作者:陆克义,Email:lu-ky@163.com
更新日期/Last Update: 2017-09-25